Sociedad Americana de Hirudoterapia

Anticoagulation in the management of neonatal cerebral sinovenous thrombosis: a systematic review and meta-analysis.

Review published in Developmental medicine and child neurology (2018)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Meta-analysisEnsayos clínicosDesarrollo de fármacosRossor et al. · Developmental medicine and child neurology, 2018

Abstract

AIM: To determine whether anticoagulation therapy (ACT) in the treatment of neonatal cerebral sinovenous thrombosis (CSVT) improves outcomes, in the presence or absence of pre-existing intracerebral haemorrhage (ICH). METHOD: We searched CENTRAL, MEDLINE, Embase, CINAHL, the Web of Science, and clinical trial databases. We considered data from retrospective and prospective cohort studies, case series, and randomized controlled studies evaluating outcomes of CSVT treated with anticoagulation or no anticoagulation. Studies were included if they involved infants either younger than 28 days of age or younger than 44 weeks postmenstrual age at the time of diagnosis of CSVT in which ACT was considered. RESULTS: Seven non-randomized studies were included in meta-analysis. ACT had no significant effect on mortality before discharge either in the presence or absence of pre-existing ICH, nor on the incidence of extension of pre-existing ICH. ACT was associated with a reduced risk of propagation of thrombus (risk ratio 0.14, 95% confidence interval 0.03-0.72). INTERPRETATION: There are no randomized trials assessing the safety and efficacy of ACT in the treatment of neonatal CSVT. The results of this meta-analysis would justify a position of equipoise and support the need for well-designed randomized controlled trials of ACT in this population. WHAT THIS PAPER ADDS: No randomized studies have evaluated anticoagulation therapy (ACT) in neonatal cerebral sinovenous thrombosis. ACT may reduce thrombus propagation. No evidence of increased morbidity or mortality with ACT was demonstrated. A position of equipoise is justified, supporting the need for placebo-controlled randomized trials.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleMeta-AnalysisSystematic Review
Indexed MeSH termsAnticoagulantsCerebral HemorrhageHumansInfant, NewbornSinus Thrombosis, Intracranial

Resumen

To determine whether anticoagulation therapy (ACT) in the treatment of neonatal cerebral sinovenous thrombosis (CSVT) improves outcomes, in the presence or absence of pre-existing intracerebral haemorrhage (ICH). We searched CENTRAL, MEDLINE, Embase, CINAHL, the Web of Science, and clinical trial databases.

Por qué esto importa para la hirudoterapia

Esta revisión sistemática y metaanálisis evaluó si la terapia anticoagulante mejora los desenlaces en la trombosis cerebral sinovenosa neonatal, analizando siete estudios no aleatorizados. Encontró que la anticoagulación puede reducir la propagación del trombo sin aumentar la mortalidad ni empeorar la hemorragia intracraneal preexistente, aunque no existen ensayos aleatorizados. Los autores solicitan ensayos aleatorizados controlados con placebo bien diseñados en esta población. El resumen no menciona sanguijuelas, hirudoterapia, hirudina ni ningún compuesto derivado de sanguijuela. Con base únicamente en este resumen, no existe una conexión defendible con el ámbito de la ASH.

Citación

Anticoagulation in the management of neonatal cerebral sinovenous thrombosis: a systematic review and meta-analysis.

Rossor et al. · Developmental medicine and child neurology, 2018

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.